ALDH1A1 and cancer: ATRA used in combination with gefitinib in cancer stem-cell-like adenocarcinoma decreased CSC-mediated resistance by reducing ALDH1A1 and CD44 expression and increasing the anticancer effects of gefitinib in NSCLC/ADC [248].